



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

THE NIHR BIOMEDICAL RESEARCH CENTRE FOR MENTAL HEALTH LONDON HAS JOINED THE METAMINER CNS PARTNERSHIP PROGRAM

St. Joseph, MI. March 24th, 2009 –GeneGo, Inc., the leading systems biology tools company, announced today that the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London (BRC-MH), has joined the MetaMiner CNS Partnership Program. Professor Simon Lovestone, Centre Director, and Dr Gerome Breen are leading the BRC-MH team for this project. The goal of the program is to develop a proprietary Central Nervous System (CNS) pathway analysis platform built by experts in the field. This includes developing a series of blue print CNS disease pathway maps for Schizophrenia, Alzheimer’s disease and Huntington’s disease, etc as well as collecting experimental data from the public domain, and making it available for analysis.

Professor Lovestone said: “This is an important initiative as it will give researchers a global perspective of CNS pathways and enable those new to the field to get up to speed quickly. Currently there is a huge amount of CNS data available but until now no one has brought it all together in a comprehensive form.”

Dr Breen, BRC-MH Genetics Coordinator, adds “Accurate and comprehensive pathway annotation is necessary for us to discern the biological mechanisms revealed by large scale omics approaches to CNS disorders, such as genomewide association and expression array studies.”

Julie Bryant, GeneGo’s VP of Business Development comments “The BRC-MH at KCL has world class expertise in CNS disorders and we are pleased to have the Centre on our team. We plan to develop excellent and accurately annotated CNS pathway maps, while fully processing experimental data taken from public repositories such as GEO. This will ultimately mean superior CNS pathway annotation and facilitate easier data analysis and exploration for our customers.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA and other data) and relevant bioactive chemistry (metabolites, drugs, other

xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) for Mental Health

The BRC for Mental Health at the South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King's College London is one of 12 national biomedical research centres created through the partnership of a leading National Health Service (NHS) provider and an outstanding university. The Centres are funded by the UK's Department of Health through the National Institute for Health Research (NIHR). The BRC for Mental Health was selected through open competition by an international expert selection panel and as such is distinguished as a leader in scientific translation. Its purpose is to accelerate the translation of fundamental biomedical research into clinical practice for patient benefit. One way it will achieve this is through the early adoption of new insights in technologies, techniques and treatments for health improvement. It is the only biomedical research centre specializing in mental health in the UK. For further information visit www.iop.kcl.ac.uk.

South London and Maudsley NHS Foundation Trust

South London and Maudsley NHS Foundation Trust provides the most extensive portfolio of mental health services in the UK, supported by internationally recognised training and research. The Trust is increasingly focussed on promoting mental health and well-being rather than simply responding to severe mental illness. The provision of integrated adult services enables the Trust to address both people's mental health and social care needs. In particular the Trust is focussing on early intervention, getting help to people sooner in the course of illnesses such as psychosis and dementia, and in supporting people with mental health problems at an earlier stage of their lives, especially young people. For further info www.slam.nhs.uk.

King's College London

King's College London is one of the top 25 universities in the world (*Times Higher Higher* 2008) and the fourth oldest in England. A research-led university based in the heart of London, King's has 19,700 students from more than 150 countries, and 5,400 employees. King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 60 per cent of research activity at King's was deemed world-leading or internationally excellent. The College is in the top group

of UK universities for research earnings and has an overall annual income of approximately £450 million. An investment of £500 million has been made in the redevelopment of its estate.